Research location
Port Montt
Los Lagos Region, Chile
Advertisement
Research activity in Port Montt
Los Lagos Region, ChileCureCurrent currently publishes aggregate city-level research activity for this location: 9 trials and 9 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Port Montt
9 linked trials · page 1 of 1Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)NCT06469944 · 2024-09-20 · 1 site observation
RECRUITING
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)NCT06445972 · 2024-08-07 · 1 site observation
RECRUITING
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)NCT06099782 · 2023-12-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)NCT05239728 · 2022-03-15 · 1 site observation
ACTIVE_NOT_RECRUITING
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).NCT05116189 · 2021-12-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)NCT05064059 · 2021-11-10 · 1 site observation
COMPLETED
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)NCT04738487 · 2021-04-07 · 1 site observation
TERMINATED
Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.NCT03220230 · 2015-07-06 · 1 site observation
COMPLETED
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary DiseaseNCT01316913 · 2011-03-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.